This activity is supported by educational grants from AstraZeneca, Clovis Oncology, Lilly, and Merck & Co.

Use of Diagnostic Tests in Advanced Non–Small Cell Lung Cancer: Skills Presentation

Beth Eaby-Sandy, MSN, CRNP, OCN®
University of Pennsylvania


The scope of knowledge and skills required to safely manage oncology patients today is daunting. Personalized medicine is becoming the standard of care as new molecular/genetic testing becomes available. This activity will provide advanced practitioners with an overview of histologic and molecular differentiation in the diagnosis and staging of non–small cell lung cancer, and how to apply that knowledge to the ordering and interpretation of diagnostic and molecular testing. 



Related Activities

Management of Patients With Cytotoxic Chemotherapy

Targeted Therapies in Advanced Non–Small Cell Lung Cancer

Management of Patients Treated With Immunotherapy

Navigating the Landscape of Molecular Testing and Treatments With Targeted Therapies for Patients With Non-Small Cell Lung Cancer

What is the role of EGFR mutations in patients with NSCLC?

What is T790m and describe its role in drug resistance?

What is ALK and how does it impact the treatment of NSCLC?

What should advanced practitioners know about the side effect profiles of targeted treatments for NSCLC?

What should pharmacists know about combining treatment agents for patients with NSCLC?

Bone Marrow Biopsy Demonstration Video



Copyright © 2016 Harborside Press, LLC All rights reserved.                Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact
Copyright Notice/Disclaimer
Bot trap - Don't go here
click me